Miyaoka D, et al. -Researchers conducted this investigation to evaluate denosumab for its renoprotective impact and involvement of denosumab-induced reduction in serum phosphorus (Pi) in osteoporotic patients. During the study period (24 months), 73 osteoporotic patients without obvious proteinuria in dipstick test results were treated with denosumab (60 mg) every 6 months. Findings suggested that the reduction in serum Pi due to phosphorus load reduction from bone induced by denosumab is a determinant for an increase in estimated glomerular filtration rate based on serum cystatin C. In cases of osteoporosis, including non-chronic kidney disease patients, early introduction of bone anti-resorptive therapy may retain glomerular filtration.